Jolivet J, Bélanger K, Yelle L, Guévin R, Potvin M, Wilson J, Rudinskas L, Latreille J, Dionne J, Gagné L
Institut du Cancer de Montréal, Québec, Canada.
Eur J Cancer. 1994;30A(5):626-8. doi: 10.1016/0959-8049(94)90533-9.
We have studied a mitoxantrone, 5-fluorouracil (5-FU) and leucovorin chemotherapy regimen in metastatic breast cancer. 8 patients received mitoxantrone 10 mg/m2 on day 1, leucovorin 200 mg/m2 and 5-FU 300 mg/m2 on days 1-5 by intravenous bolus every 28 days in a pilot study. Grades 3-4 granulocytopenia followed 55% of the courses, with 2 patients admitted for febrile neutropenia. Only a 29% objective response rate was seen in a subsequent phase II trial using reduced mitoxantrone doses. Comparison with other trials suggested that 5-day bolus 5-FU administration adversely affects the combination's therapeutic index.
我们研究了米托蒽醌、5-氟尿嘧啶（5-FU）和亚叶酸钙化疗方案用于转移性乳腺癌的情况。在一项初步研究中，8例患者每28天接受一次静脉推注，第1天给予米托蒽醌10mg/m²，第1 - 5天给予亚叶酸钙200mg/m²和5-FU 300mg/m²。55%的疗程出现3 - 4级粒细胞减少，2例患者因发热性中性粒细胞减少而入院。在随后一项使用降低剂量米托蒽醌的II期试验中，仅观察到29%的客观缓解率。与其他试验的比较表明，5天推注5-FU给药对该联合方案的治疗指数有不利影响。
